S25 Controversies in Chronic Kidney Disease-Metabolic Bone Disease

Program: Symposia
Clinical Session
Friday, March 6, 2015: 9:30 AM-11:00 AM
Room 29 (San Diego Convention Center)
**This session is eligible for CME credit**

Suzanne Marie Jan De Beur, MD, Johns Hopkins Univ Sch of Med, Baltimore, MD

Nothing to Disclose: SMJ Disclosure Not Provided: HR

There is uncertainty about the evaluation and management of metabolic bone disease in the setting of chronic kidney disease. This symposium addresses new and emerging concepts on pathophysiology and management.

9:30 AM
Sharon M. Moe, MD, Medicine, Division of Nephrology, Indiana University, Indianapolis, IN
Nothing to Disclose: SMM
10:00 AM
Myles Wolf, M.D., MMSc, Institute for Public Health and Medicine, Northwestern University, Chicago, IL
Disclosure: MW: Committee Member, Amgen, Committee Member, OPKD, Committee Member, Keryx, Committee Member, Pfizer, Inc., Committee Member, Luitpold, Speaker, Sanofi, Speaker, Shire.
10:30 AM
Roland Chapurlat, INSERM UMR 1033, UniversitÚ de Lyon, H˘pital Edouard Herriot, Lyon, France
Disclosure: RC: Advisory Group Member, Amgen, Independent Contractor (including contracted research), Eli Lilly & Company, Independent Contractor (including contracted research), Merck & Co., Clinical Researcher, Merck & Co., Clinical Researcher, Servier, Independent Contractor (including contracted research), Novartis Pharmaceuticals, Independent Contractor (including contracted research), Roche Pharmaceuticals.
See more of: Symposia